Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose Expansion Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CPL-01 in Postoperative Pain After Open Inguinal Herniorrhaphy

NCT05080959 is registered in ClinicalTrials.gov with Cali Pharmaceuticals LLC as lead sponsor.

NCT NCT05080959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05080959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose Expansion Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CPL-01 in Postoperative Pain After Open Inguinal Herniorrhaphy
Lead sponsor
Cali Pharmaceuticals LLC
Phase
Phase 2
Overall status
Completed
Start date
July 28, 2021
Completion date
June 10, 2022
Enrollment
105 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

inguinal herniorrhaphy